Investigational drug study may determine if lung cancer is preventable in cigarette smokers
10/12/00
CHICAGO --- Researchers at The Robert H. Lurie Comprehensive Cancer Center of Northwestern University are seeking participants for a study of an investigational drug that may prevent cigarette smokers from developing lung cancer.
Cigarette smoke contains chemicals that become carcinogens when initially metabolized by the human body.
The National Cancer Institute-sponsored study will determine if the experimental drug may be able to decrease the amount of carcinogens produced from inhaled cigarette smoke.
The principal investigator for the study is Raymond C. Bergan, M.D., assistant professor of medicine at Northwestern University Medical School and a researcher at the Cancer Center.
To qualify for the investigational drug study, participants must be at least 18 years old and have no medical problems. Participants currently must smoke at least 20 cigarettes a day, have smoked to some degree for at least 10 years and have at least one failed attempt to quit smoking in the past three years. The number of cigarettes smoked per day must be fairly constant for three months prior to entering the study.
Cigarettes
